Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Pulmonary hypertension in patients with interstitial lung disease: a tool for early detection

Abstract Pulmonary hypertension (PH) complicates the treatment of interstitial lung disease (ILD) patients resulting in poor functional status and worse outcomes. Early recognition of PH in ILD is important for initiating therapy and considering lung transplantation. However, no standard exists rega...

Volledige beschrijving

Bibliografische gegevens
Hoofdauteurs:	Raj Parikh, Ippokratis Konstantinidis, David M. O'Sullivan, Harrison W. Farber
Formaat:	Artikel
Taal:	English
Gepubliceerd in:	Wiley 2022-10-01
Reeks:	Pulmonary Circulation
Onderwerpen:	idiopathic pulmonary fibrosis interstitial lung disease prostacyclin pulmonary hypertension treprostinil
Online toegang:	https://doi.org/10.1002/pul2.12141

Gelijkaardige items

The PH‐ILD Detection tool: External validation and use in patients with ILD
door: Raj Parikh, et al.
Gepubliceerd in: (2023-07-01)

Failure to tolerate continuous subcutaneous treprostinil in pediatric pulmonary hypertension patients
door: Julia McSweeney, et al.
Gepubliceerd in: (2023-04-01)

Evaluation of patients with severe pulmonary hypertension and a range of comorbidities prescribed inhaled treprostinil
door: Aparna C. Swaminathan, et al.
Gepubliceerd in: (2024-11-01)

Case Report: Selexipag in pediatric pulmonary hypertension: Initiation, transition, and titration
door: Jenna M. Faircloth, et al.
Gepubliceerd in: (2023-03-01)

Corrigendum: Case report: Selexipag in pediatric pulmonary hypertension: initiation, transition, and titration
door: Jenna M. Faircloth, et al.
Gepubliceerd in: (2023-08-01)

The Importance of Dose Escalation in the Treatment of Pulmonary Arterial Hypertension with Treprostinil
door: Piotr Kędzierski, et al.
Gepubliceerd in: (2025-01-01)

Inhaled therapies targeting prostacyclin pathway in pulmonary hypertension due to COPD: systematic review
door: Abdullah A. Alqarni, et al.
Gepubliceerd in: (2023-08-01)

Real‐world use of inhaled treprostinil for lung disease‐pulmonary hypertension: A protocol for patient evaluation and prescribing
door: Shelsey W. Johnson, et al.
Gepubliceerd in: (2022-07-01)

INSPIRE: Safety and tolerability of inhaled Yutrepia (treprostinil) in pulmonary arterial hypertension (PAH)
door: Nicholas S. Hill, et al.
Gepubliceerd in: (2022-07-01)

Evolution of pulmonary hypertension in interstitial lung disease: a journey through past, present, and future
door: Ahmad Arslan, et al.
Gepubliceerd in: (2024-01-01)

PAH-specific therapy for pulmonary hypertension and interstitial lung disease: A systemic review and meta-analysis
door: Ning Zhao, et al.
Gepubliceerd in: (2022-11-01)

Pulmonary Fibrosis and Progressive Pulmonary Fibrosis in a Prospective Registry of Interstitial Lung Diseases in Eastern Siberia
door: Maria S. Nashatyreva, et al.
Gepubliceerd in: (2023-01-01)

Unexpected Acceleration in Treprostinil Delivery Administered by a Lenus Pro® Implantable Pump in Two Patients Treated for Pulmonary Arterial Hypertension
door: Garance Kopp, et al.
Gepubliceerd in: (2020-10-01)

Reasons for refusing parenteral therapy: a qualitative study of patients with pulmonary arterial hypertension
door: Kellie Morland, et al.
Gepubliceerd in: (2021-10-01)

Interstitial Lung Abnormality in Asian Population
door: Gong Yong Jin
Gepubliceerd in: (2024-04-01)

The application of metabolomics toward idiopathic pulmonary fibrosis and potential metabolomic value of diverse samples in interstitial lung diseases
door: Mingtao Liu, et al.
Gepubliceerd in: (2023-09-01)

CLINICAL PROFILE OF INTERSTITIAL LUNG DISEASES CASES
door: Gagiya Ashok K, et al.
Gepubliceerd in: (2012-03-01)

Converging Pathways: A Review of Pulmonary Hypertension in Interstitial Lung Disease
door: Alexandra Lawrence, et al.
Gepubliceerd in: (2024-09-01)

Pulmonary Hypertension in Interstitial Lung Disease: Updates in Disease, Diagnosis, and Therapeutics
door: Zachary A. Haynes, et al.
Gepubliceerd in: (2023-10-01)

Prostacyclin receptor agonist selexipag in a patient with high-risk idiopathic pulmonary arterial hypertension: a case report
door: E. A. Rezukhina, et al.
Gepubliceerd in: (2021-09-01)

Interstitial lung diseases with progressive pulmonary fibrosis: pathogenetic features and approaches to therapy
door: N. A. Kuzubova, et al.
Gepubliceerd in: (2020-11-01)

Therapeutic Potential of Treprostinil Inhalation Powder for Patients with Pulmonary Arterial Hypertension: Evidence to Date
door: Cassady SJ, et al.
Gepubliceerd in: (2024-06-01)

Osteopontin as a Biomarker in Interstitial Lung Diseases
door: David Iturbe-Fernández, et al.
Gepubliceerd in: (2024-05-01)

Multidisciplinary discussion for diagnosis of interstitial lung disease in real life
door: Sabina Anna Guler, et al.
Gepubliceerd in: (2016-05-01)

Increased expiratory flows identify early interstitial lung disease
door: Sami Mohammed Alyami, et al.
Gepubliceerd in: (2023-01-01)

Role of Telomere Length in Survival of Patients with Idiopathic Pulmonary Fibrosis and Other Interstitial Lung Diseases
door: Sofía Tesolato, et al.
Gepubliceerd in: (2023-12-01)

Digital quantification of p16-positive foci in fibrotic interstitial lung disease is associated with a phenotype of idiopathic pulmonary fibrosis with reduced survival
door: Jonathan Keow, et al.
Gepubliceerd in: (2022-06-01)

Efficacy of oral treprostinil for treating pulmonary arterial hypertension: a systematic review and meta-analysis
door: Lianghua Xiao, et al.
Gepubliceerd in: (2024-09-01)

Evaluation of progressive pulmonary fibrosis in non-idiopathic pulmonary fibrosis-interstitial lung diseases: a cross-sectional study
door: Özlem Erçen Diken, et al.
Gepubliceerd in: (2024-08-01)

Estimation of plasmic concentration of the brain natriuretic peptide in interstitial pulmonary diseases with pulmonary hypertension: clinical role
door: N A Mukhin, et al.
Gepubliceerd in: (2009-03-01)

Altered prostanoid production by fibroblasts cultured from the lungs of human subjects with idiopathic pulmonary fibrosis
door: Pierson Richard, et al.
Gepubliceerd in: (2002-02-01)

Abnormal platelet aggregation in pediatric pulmonary hypertension
door: Stephanie S. Handler, et al.
Gepubliceerd in: (2022-07-01)

Comorbid Conditions in Idiopathic Pulmonary Fibrosis: Recognition and Management
door: Justin M. Oldham, et al.
Gepubliceerd in: (2017-08-01)

Interstitial lung abnormalities in a large clinical lung cancer screening cohort: association with mortality and ILD diagnosis
door: Avignat S. Patel, et al.
Gepubliceerd in: (2023-02-01)

Selexipag in the treatment of pulmonary arterial hypertension: design, development, and therapy
door: Hardin EA, et al.
Gepubliceerd in: (2016-11-01)

Bibliometric analysis of the pirfenidone and nintedanib in interstitial lung diseases
door: Jia Liu, et al.
Gepubliceerd in: (2024-04-01)

Severe bronchospasm and acute respiratory failure associated with inhaled prostacyclin therapy
door: Donna Steinbacher, et al.
Gepubliceerd in: (2024-04-01)

A Case of Interstitial Lung Disease-Related Pulmonary Hypertension Successfully Treated with Inhaled Iloprost
door: Ji Hoon Jang, et al.
Gepubliceerd in: (2024-08-01)

The effects of standardized intravenous treprostinil in pulmonary arterial hypertension patients after total cavo-pulmonary connection procedure
door: Xiaofeng Wang, et al.
Gepubliceerd in: (2024-10-01)

An observational cohort study of interstitial lung abnormalities (ILAs) in a large Japanese health screening population (Kumamoto ILA study in Japan: KILA-J)
door: Kazuya Ichikado, et al.
Gepubliceerd in: (2023-06-01)